Loading…
Loading…
EQUITY / NASDAQ · XNCM
Greenwich LifeSciences, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗18.05 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 18.05 USD · Volume 145,109
62 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -4,021,645 USD | -3,769,315 USD | — |
| Net income | -3,948,675 USD | -3,748,640 USD | — |
| Total liabilities | 5,759,396 USD | — | — |
| Total equity | 3,116,957 USD | 604,302 USD | +415.79% |
| Total assets | 8,876,353 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end07/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Net incomeIncome statement | -3,948,675 USD | -9,605,812 USD | -5,657,137 USD | — | -19,358,218 USD | -3,711,269 USD | -10,204,689 USD | -3,748,640 USD |
| Operating profitIncome statement | -4,021,645 USD | -9,747,399 USD | — | — | -19,447,918 USD | — | — | -3,769,315 USD |
| Total assetsBalance sheet | 8,876,353 USD | — | — | 6,178,021 USD | 6,178,021 USD | — | — | — |
| Total equityBalance sheet | 3,116,957 USD | — | 5,270,206 USD | 353,217 USD | 353,217 USD | — | — | 604,302 USD |
| Total liabilitiesBalance sheet | 5,759,396 USD | — | — | 5,824,804 USD | 5,824,804 USD | 2,016,615 USD | — | — |
| Financing cash flowCash flow statement | — | 9,340,576 USD | — | — | 11,999,484 USD | — | — | — |
| Operating cash flowCash flow statement | — | -6,642,244 USD | — | — | -9,913,453 USD | — | -6,738,796 USD | — |
| Cash and cash equivalentsBalance sheet | — | — | — | — | 6,178,021 USD | — | — | — |
| Report source | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 08/11/2026 | Open report ↗ Published: 06/01/2026 | Open report ↗ Published: 06/01/2026 | Open report ↗ Published: 06/01/2026 | Open report ↗ Published: 08/11/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.